Full Breakdown
U.S. Trade Probe Targets German Drug Pricing
6/28/2026, 9:21:51 PM
Trade Probe Initiated
In June 2024 the United States invoked Section 301 to launch a probe of Germany’s pharmaceutical pricing system, with a possible September conclusion and the prospect of tariffs on German drug exports.
Divergent Pricing Systems
Germany caps drug prices through centrally negotiated reimbursements under its public health-insurance scheme, while the United States uses market-driven pricing and pharmacy-benefit managers. The U.S. previously applied Section 301 to Switzerland over alleged market distortion.
Key Figures
Key figures are U.S. Trade Representative Jamieson Greer, President Donald Trump, German Health Minister Nina Warken, Chancellor Friedrich Merz, and the three U.S. PBMs—CVS Caremark, Express Scripts, Optum Rx.
Core Data
In 2023 U.S. patients spent $1,713 per person on medicines, versus $1,158 in Germany. Boehringer’s Jardiance costs about €80 a month in Germany but roughly €300 in United States. 20 % of German pharmaceutical exports go to United States. Deloitte projects tariffs of 10-35 % could cut those exports by 5-53 %, a loss of €1.3-13.4 billion.
Implications
If tariffs are imposed, U.S. patients could face higher prices or reduced availability of German medicines, while German producers risk losing a sizable share of world’s largest pharmaceutical market. The case highlights disputes over R&D cost allocation.
Official Statements
Jamieson Greer said investigation will determine whether Germany’s pricing is unreasonable or discriminatory and burdens U.S. commerce. Administration cited President Trump’s view that American patients should not shoulder a disproportionate share of R&D costs. German officials said reimbursement levels are set federally and that health-insurance funds face financial strain, offering cooperation.
Opposition & Critique
The Federal Trade Commission has opened investigations into three largest PBMs for anti-competitive discounting that may inflate drug prices. German experts argue that central price negotiations and therapeutic-value assessments are legitimate mechanisms to keep medicines affordable and view U.S. probe as an overreach.
Conflicting Evidence
German analyses emphasize overall higher drug costs, while U.S. officials stress the burden on uninsured patients. Both sides note limited transparency in pricing mechanisms, leaving gaps in comparative data.
Verbatim Quotes
"This investigation will seek to determine whether persistent underpayment for innovative pharmaceutical products by Germany is unreasonable or discriminatory and burdens or restricts US commerce." — Jamieson Greer, U.S. Trade Representative
"Reimbursement for modern, innovative medication through our health insurance funds is determined at the federal level." — Friedrich Merz, Chancellor of Germany
"The financial situation at Germany's health insurance funds is strained, so it will be tough to pay higher prices." — Nina Warken, German Health Minister
"Add to that the fact that manufacturers in Germany must prove that new drugs have added therapeutic value over existing therapeutic standards when setting prices." — Susanne Uhlmann, Deloitte partner
Next Steps
The probe will conclude in September; Germany’s health-savings package is expected to be voted on soon, and any adverse findings could trigger tariffs.
